161P Queen Elizabeth II Conference Centre London
BPS Winter Meeting 2012

 

 

Effects Of Selective Blockade Of EP1, EP2 And TP Receptors In Antigen-Induced Contractions In The Guinea-pig Trachea

Jesper Säfholm J1, Sven-Erik Dahlén SE1, Lars-Olaf Cardell LO2, Mikael Adner M1. 1Unit for Experimental Asthma and Allergy Research, Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 2Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden

 

Histamine and cysteinyl-leukotrienes are established mediators responsible for antigen-induced bronchoconstriction in humans and guinea-pigs (GP). However, the experiments in isolated smooth muscle preparations have been made in the presence of inhibitors of the cyclo-oxygenase (COX) reaction that catalyse biosynthesis of prostaglandins (PG), leaving considerable uncertainty about the role of different COX products for the response to antigen.

The aim of this study was to characterise the role of COX metabolites in the antigen-induced contraction of the GP trachea using selective inhibitors and antagonists. Since constitutively released PGE2 maintains a powerful tone in the GP trachea, the effect of other potential COX metabolites during the antigen-induced contraction were investigated comparing the effect of COX-inhibition with selective antagonism of EP1-2 receptors plus other PG receptors.

Male albino GP (Dunkin-Hartley;400-450g) were sensitized by single peritoneal injections containing 100µg ovalbumin (OVA) and 0.1g Al(OH)3 and humanely killed 14 days later by sodium pentobarbital. Intact tracheal ring-segments were placed in tissue organ-baths containing Krebs-Ringer PSS at 37°C. Cumulative concentrations of OVA (0.1ng/mL to 0.1mg/mL) were administrated in the absence and presence inhibitors/antagonists which were given 45min prior. Pharmacological tools used were; COX-inhibitor (indomethacin;3µM) and 5-lipoxygenase-activating protein (FLAP)-inhibitor (MK-886;10µM) as well as receptor antagonists for EP1 (ONO-8130;0.1µM), EP2 (PF-04418948;10µM), TP (SQ-29,548;1µM), H1 (mepyramine;1µM) and H2 (metiamide;1µM). Isometrical force was measured compared to maximal contraction (histamine;1mM, acetylcholine;1mM and KCl;60mM) in relation to maximal relaxation (papaverine;0.1mM and sodium nitroprusside;0.1mM). Statistical analysis was performed using One-Way ANOVA.

In controls, challenge with OVA induced concentration-dependent contractions from a basal tone of 35% reaching 76%, compared to the maximal tissue response (Table 1). Both COX-inhibition and antagonism of the EP1 receptors abolished the basal tone (p<0.05), however, the antigen-induced contraction was greater in amplitude in presence of COX inhibition (p<0.05) compared to EP1 receptor antagonism (p<0.05). Inhibition of FLAP and H1-2 receptors had no significant effects on the antigen-induced contraction when given separately but a significant inhibition was observed when administered in combination in the presence of either COX inhibition or EP1 antagonism (p<0.05). Moreover, the antigen-induced contraction was completely abolished when the TP receptor antagonist was added to FLAP inhibition and antihistamines after EP1 antagonism (p<0.05). Irrespective of which drugs that were used to block other pathways, addition of the EP2 receptor antagonist increased the antigen-induced contraction with 25% (p<0.05).

In conclusion, by selectively antagonising the EP1-2 receptors it was possible to unmask a substantial component of the antigen-induced contraction that was mediated by a mediator acting on the TP receptor. This component has not been possible to assess in previous experiments when the powerful effect of PGE2 is unopposed.

Table 1: Initial tone and Emax in GP trachea in response to ovalbumin

Treatment Initial tone (% of max) Emax (% of max)
Control 35.4±4.9 75.9±2.4
I 0.6±3.8 87.1±3.9
O 2.7±2.6 57.7±1.6
IMk 1.8±4.0 89.7±2.7
IM 1.9±2.1 91.0±4.3
IMMk 0.1±2.3 38.0±2.9
OMMk 2.6±2.3 23.1±1.6
OSMMk 0 0
OP 1.9±0.3 83.8±2.8
OPMMk 0.1±4.4 47.6±3.4
OSPMMk 0.3±2.4 28.0±2.7

I=Indomethacin, O=ONO-8130, Mk=MK-886, M=mepyramine&metiamid, S=SQ-29,548 and P=PF-04418948. All data are presented as mean±SEM (n=8-23).